Fig. 3: Silencing NEK6 inhibits de novo purine synthesis and chemoresistance in ovarian cancer cells. | Cell Death & Disease

Fig. 3: Silencing NEK6 inhibits de novo purine synthesis and chemoresistance in ovarian cancer cells.

From: NEK6 dampens FOXO3 nuclear translocation to stabilize C-MYC and promotes subsequent de novo purine synthesis to support ovarian cancer chemoresistance

Fig. 3

A mRNA levels of NEK6 knockdown. N = 3. Data presented as mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001; ANOVA. B Western blot reveals protein levels of NEK6 knockdown. N = 3. Data presented as mean ± SD. **P < 0.01; ***P < 0.001; ANOVA. C Flow cytometry detection of apoptosis levels in cells after NEK6 knockdown and purine supplementation or depletion, followed by 24 h of DOX treatment (60 µM DOX for NCI/ADR-RES and 30 µM DOX for SKOV3/DDP). N = 3. Data presented as mean ± SD. ***P < 0.001; ns not significant; ANOVA. D Quantification of DOX uptake levels in each group using flow cytometry in NCI/ADR-RES and SKOV3/DDP cells. N = 3. Data presented as mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001; ANOVA. E Alkaline comet assay performed on NCI/ADR-RES and SKOV3/DDP cells under different treatment conditions, with tail moment quantification. N = 20. F Observation of γH2AX and RAD51 foci levels after purine supplementation in NEK6 knockdown cells following 2 h of DOX-induced DNA damage and repair. N = 5. Data presented as mean ± SD. **P < 0.01; ***P < 0.001; ns not significant; ANOVA. G Growth curves of ovarian cancer xenografts under NEK6 knockdown or purine intervention. N = 5. Data presented as mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001; ANOVA. H Endpoint images of ovarian cancer xenografts obtained at the endpoint.

Back to article page